" class="no-js "lang="en-US"> Adel Nada - Medtech Alert
Thursday, March 30, 2023
Adel Nada

Adel Nada

About Adel Nada


Adel Nada is Co-founder and Chief Executive Officer of GentiBio. Prior to joining GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics where he worked on advancing engineered regulatory T cell (Tregs) therapeutics. In the past, Adel has held executive positions in various biotech and pharmaceutical companies, including Vice President at Intellia Therapeutics and Caladrius Biosciences, and various senior positions directing clinical development at Baxter and Abbott. He successfully led translational immunology programs over past 15 years for experimental and approved therapies, spanning small and large molecules and engineered immune cell products, including Tregs products. Adel received his medical degree from Alexandria University in Egypt and his master’s degree in Clinical Research from the Pharmacology Dept. at Rush University in Chicago where he also held an academic position. Adel completed advanced studies in drug development at UCSF and University of Basel before becoming a Member of the Faculty of Pharmaceutical Medicine in the UK. Prior to joining the industry, Adel trained in surgery and internal medicine and practiced for 10 years in Chicago. When not preoccupied with Tregs and inflammation, he focuses his constant curiosity on reading and exploring new people, ideas and places. Adel also enjoys long distance running, street photography, and meditation.


Related Story

GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases

September 15 2022

GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, […]

GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases

August 10 2022

GentiBio, Inc., an engineered regulatory T cells (Tregs) company,  announced today that it has entered […]